HCP Engagement Metrics: What Each Signal Can Actually Support
An evidence ladder for HCP media metrics, showing which decisions delivery, attention, action, and outcome signals can and cannot support.
The short answer
HCP campaign reports are full of metrics. Impressions, viewability, click-through, video completion, site visits, time on site, and eventually new prescriptions. The mistake is not reporting them. The mistake is using a metric to support a decision it cannot support. An evidence ladder makes those limits explicit.
The evidence ladder
| Rung | Examples | Can support | Cannot support |
|---|---|---|---|
| Delivery | Impressions to verified NPIs, viewability, invalid traffic rate | Pacing, partner delivery checks, quality controls | Claims that prescribers paid attention or changed behavior |
| Attention proxy | Video completion, time in view, scroll depth | Creative and placement comparisons | Claims about clinical understanding or intent |
| Action | Site visits, content downloads, sample or rep requests | Channel and message optimization, journey analysis | Claims that media caused prescribing |
| Associated outcome | Attributed NRx or TRx among exposed prescribers | Directional partner comparison, hypothesis generation | Size of media's causal effect |
| Incremental outcome | Lift versus a comparison group with a stated interval | Investment and renewal decisions | Transfer to different brands or years without new evidence |
Why clicks are weak for HCP
Click-through rates on HCP display are low and noisy. Clicks can come from accidental taps, especially on mobile, and from invalid traffic. They also correlate poorly with prescribing. Use clicks for creative testing at most. Do not use them to choose partners.
Attention proxies need context
Completion rates depend on format. A 15-second unskippable video will almost always complete more often than a 60-second skippable one. Compare completion within the same format and placement type. See the video quality scorecard for a fuller view of video quality.
Actions are useful, with care
Site visits and content engagement are the most useful mid-funnel signals for HCP media. They show that a prescriber acted after exposure. They are still associative. Prescribers who were already interested are more likely to both see ads and visit the site. Treat action data as a guide for optimization and a source of hypotheses.
Outcome metrics need a label
Attributed prescriptions are often presented as proof of impact. They are not. They show prescriptions among exposed prescribers under a rule. The difference between attributed and incremental prescriptions is the most important distinction in this ladder. Only a comparison-based design can support claims about how many prescriptions media caused. The ASA's statement on p-values is a useful reminder that a significant result is not the same as an important one.
Choosing KPIs
Pick one primary KPI per decision:
- Pacing decisions: verified delivery to the list.
- Creative decisions: attention proxies within format.
- Channel mix decisions: actions per dollar, with a note about selection effects.
- Renewal decisions: incremental outcomes, or associated outcomes clearly labeled as such if incrementality is unavailable.
Practical takeaway
Add a column to your KPI table that says which rung each metric sits on. When someone uses a lower-rung metric to justify a higher-rung decision, the table makes the gap visible.
Sources
- Media Rating Council, Standards and Guidelines
- American Statistical Association, Statement on p-Values
- FDA Office of Prescription Drug Promotion
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.